Patent denied, price of prostate cancer drug may go down

The Indian Patent Office has denied a patent to Xtandi (Enzalutamide), a steeply-priced wonder drug used in prostate cancer, on the pre-grant opposition filed by a clutch of entities, including Mumbai-based BDR Pharma, drug company Fresenius Kabi and Indian Pharmaceutical Alliance. The refusal to grant a patent paves the way for the entry of drug's generic version at a fraction of the price - at least 60-70% cheaper. At present, Japan's Astellas Pharma sells the drug in India at Rs 3.35 lakh for a pack of 112 capsules for a month's dose.

http://health.economictimes.indiatimes.com/news/pharma/patent-denied-price-of-prostate-cancer-drug-may-go-down/55344613